- Home
- RBNE vs GNPX Comparison
RBNE vs GNPX Comparison
Compare RBNE & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBNE
- GNPX
- Stock Information
- Founded
- RBNE 2024
- GNPX 2009
- Country
- RBNE Cyprus
- GNPX United States
- Employees
- RBNE N/A
- GNPX N/A
- Industry
- RBNE Marine Transportation
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- RBNE Consumer Discretionary
- GNPX Health Care
- Exchange
- RBNE Nasdaq
- GNPX Nasdaq
- Market Cap
- RBNE 7.3M
- GNPX 6.6M
- IPO Year
- RBNE N/A
- GNPX 2018
- Fundamental
- Price
- RBNE $2.79
- GNPX $0.28
- Analyst Decision
- RBNE
- GNPX
- Analyst Count
- RBNE 0
- GNPX 0
- Target Price
- RBNE N/A
- GNPX N/A
- AVG Volume (30 Days)
- RBNE 9.9M
- GNPX 3.5M
- Earning Date
- RBNE 08-21-2025
- GNPX 08-08-2025
- Dividend Yield
- RBNE N/A
- GNPX N/A
- EPS Growth
- RBNE N/A
- GNPX N/A
- EPS
- RBNE N/A
- GNPX N/A
- Revenue
- RBNE N/A
- GNPX N/A
- Revenue This Year
- RBNE N/A
- GNPX N/A
- Revenue Next Year
- RBNE N/A
- GNPX N/A
- P/E Ratio
- RBNE N/A
- GNPX N/A
- Revenue Growth
- RBNE N/A
- GNPX N/A
- 52 Week Low
- RBNE $2.38
- GNPX $0.20
- 52 Week High
- RBNE $20.57
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- RBNE N/A
- GNPX 52.82
- Support Level
- RBNE N/A
- GNPX $0.25
- Resistance Level
- RBNE N/A
- GNPX $0.27
- Average True Range (ATR)
- RBNE 0.00
- GNPX 0.03
- MACD
- RBNE 0.00
- GNPX 0.00
- Stochastic Oscillator
- RBNE 0.00
- GNPX 66.27
About RBNE Robin Energy Ltd. Common Stock
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.